Serial FLT PET Imaging in Cancer Patients for Monitoring of Response to Therapy

Status: Withdrawn
Location: See location...
Intervention Type: Radiation, Device
Study Type: Interventional
Study Phase: Not Applicable

The purpose of this study is to see if PET/CT scans that use a radioactive substance called [18F] fluorothymidine (FLT), can detect and monitor changes in the tumor. Radioactive substances are used with PET/CT scans to see cancer cells, and are also called radiotracers. FLT is a new radiotracer that has been given to people in prior studies. FLT PET/CT is an experimental scan unlike FDG (fluorodeoxyglucose) PET scan which is a standard clinical scan and is commonly used. The investigators would like to know if there is any evidence of early treatment response by obtaining FLTPET/ CT scans before and after treatment.

Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: No

• Patients with histologically-confirmed (confirmation done at MSKCC) malignancies.

• Patients who have consented to a therapeutic protocol for the treatment of their cancer.

• Patients must be ≥ 18 years old.

United States
New York
Memorial Sloan Kettering Cancer Center
New York
Time Frame
Start Date: May 2014
Completion Date: May 2020
Experimental: Serial FLT PET Imaging
Patients will receive a target injection of up to 10 mCi of FLT. Optionally, dynamic PET imaging over a chosen index lesion (based on size and/or high FDG-avidity on preceding CT and/or FDG PET/CT scans done for clinical purpose such as staging), may be performed. Otherwise, static PET images are obtained at approximately 60 min (+15 min) post FLT injection. In general this body scan will cover at least the region from skull base to the upper thigh for extracranial malignancies; depending on the specific location, extremities maybe also be scanned (e.g., extremity sarcoma), or the scan may be restricted to the brain (e.g. glioma).
Leads: Memorial Sloan Kettering Cancer Center

This content was sourced from

Similar Clinical Trials